|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项评估 SKG0106 眼内注射溶液在新生血管性年龄相关性黄斑变性(nAMD) 患者中的安全性、耐受性、疗效探索性 I/II 期临床研究
[Translation] An exploratory Phase I/II clinical study to evaluate the safety, tolerability and efficacy of SKG0106 intraocular injection solution in patients with neovascular age-related macular degeneration (nAMD)
评估SKG0106的眼部和全身安全性及耐受性;
确定SKG0106的MTD和/或II期临床试验推荐剂量(RP2D);
评估SKG0106的初步疗效。
[Translation] Evaluate the ocular and systemic safety and tolerability of SKG0106;
Determine the MTD and/or recommended dose (RP2D) for Phase II clinical trials of SKG0106;
Evaluate the preliminary efficacy of SKG0106.
100 Clinical Results associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
0 Patents (Medical) associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
100 Deals associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
100 Translational Medicine associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.